1imr
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1imr.gif|left|200px]] | [[Image:1imr.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1imr", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | | | + | or leave the SCENE parameter empty for the default display. |
| - | | | + | --> |
| - | + | {{STRUCTURE_1imr| PDB=1imr | SCENE= }} | |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''MOLECULAR STRUCTURE OF THE HALOGENATED ANTI-CANCER DRUG IODODOXORUBICIN COMPLEXED WITH D(TGTACA) AND D(CGATCG)''' | '''MOLECULAR STRUCTURE OF THE HALOGENATED ANTI-CANCER DRUG IODODOXORUBICIN COMPLEXED WITH D(TGTACA) AND D(CGATCG)''' | ||
| Line 19: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
| - | + | Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1IMR OCA]. | |
==Reference== | ==Reference== | ||
Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG)., Berger I, Su L, Spitzner JR, Kang C, Burke TG, Rich A, Nucleic Acids Res. 1995 Nov 11;23(21):4488-94. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/7501474 7501474] | Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG)., Berger I, Su L, Spitzner JR, Kang C, Burke TG, Rich A, Nucleic Acids Res. 1995 Nov 11;23(21):4488-94. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/7501474 7501474] | ||
| - | [[Category: Protein complex]] | ||
[[Category: Berger, I.]] | [[Category: Berger, I.]] | ||
[[Category: Burke, T G.]] | [[Category: Burke, T G.]] | ||
| Line 30: | Line 26: | ||
[[Category: Spitzner, J R.]] | [[Category: Spitzner, J R.]] | ||
[[Category: Su, L.]] | [[Category: Su, L.]] | ||
| - | [[Category: | + | [[Category: Complexed with drug]] |
| - | [[Category: | + | [[Category: Double helix]] |
| - | [[Category: | + | [[Category: Right handed dna]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 20:09:59 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 17:10, 2 May 2008
MOLECULAR STRUCTURE OF THE HALOGENATED ANTI-CANCER DRUG IODODOXORUBICIN COMPLEXED WITH D(TGTACA) AND D(CGATCG)
Overview
4'-Deoxy-4'-iododoxorubicin, a halogenated anthracycline derivative, is an anticancer agent currently under Phase II clinical trials. In preclinical studies, it has demonstrated significantly reduced levels of cardiotoxicity compared to currently employed anthracyclines. It also has modified pharmacological properties resulting in an altered spectrum of experimental antitumor activity. The iodine atom at the 4' position of the sugar ring reduces the basicity and enhances the lipophilicity of this compound as compared to related anthracycline drugs. We report here single crystal X-ray diffraction studies of the complexes of 4'-deoxy-4'-iododoxorubicin with the hexanucleotide duplex sequences d(TGTACA) and d(CGATCG) at 1.6 and 1.5 A, respectively. The iodine substituent does not alter the geometry of intercalation as compared to previously solved anthracycline complexes, but appears to markedly affect the solvent environment of the structures. This could have consequences for the interaction of this drug with DNA and DNA binding proteins in cells.
About this Structure
Full crystallographic information is available from OCA.
Reference
Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG)., Berger I, Su L, Spitzner JR, Kang C, Burke TG, Rich A, Nucleic Acids Res. 1995 Nov 11;23(21):4488-94. PMID:7501474 Page seeded by OCA on Fri May 2 20:09:59 2008
